CN105899211A - 使用cbp/连环蛋白的抑制剂治疗肝纤维化 - Google Patents

使用cbp/连环蛋白的抑制剂治疗肝纤维化 Download PDF

Info

Publication number
CN105899211A
CN105899211A CN201480057194.7A CN201480057194A CN105899211A CN 105899211 A CN105899211 A CN 105899211A CN 201480057194 A CN201480057194 A CN 201480057194A CN 105899211 A CN105899211 A CN 105899211A
Authority
CN
China
Prior art keywords
optionally substituted
triazine
dioxo
methyl
pyrazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480057194.7A
Other languages
English (en)
Chinese (zh)
Inventor
小路弘行
小田上刚直
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN105899211A publication Critical patent/CN105899211A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201480057194.7A 2013-10-18 2014-10-17 使用cbp/连环蛋白的抑制剂治疗肝纤维化 Pending CN105899211A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361892606P 2013-10-18 2013-10-18
US61/892606 2013-10-18
PCT/IB2014/002846 WO2015056104A2 (en) 2013-10-18 2014-10-17 Treatment of hepatic fibrosis using an inhibitor of cbp/catenin

Publications (1)

Publication Number Publication Date
CN105899211A true CN105899211A (zh) 2016-08-24

Family

ID=52828810

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480057194.7A Pending CN105899211A (zh) 2013-10-18 2014-10-17 使用cbp/连环蛋白的抑制剂治疗肝纤维化

Country Status (5)

Country Link
US (1) US20160263131A1 (enExample)
EP (1) EP3057590B1 (enExample)
JP (1) JP6507336B2 (enExample)
CN (1) CN105899211A (enExample)
WO (1) WO2015056104A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014092154A1 (ja) 2012-12-12 2014-06-19 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ 肝線維症の予防または治療剤
EP3490987B1 (en) * 2016-07-29 2022-09-21 Guangzhou Lupeng Pharmaceutical Company Ltd. Novel therapeutic agents for the treatment of hbv infection
KR20180045213A (ko) * 2016-10-25 2018-05-04 경상대학교산학협력단 Icg-001을 함유하는 섬유증의 예방 또는 치료용 약학 조성물
EP3596055A1 (en) * 2017-03-15 2020-01-22 Ziylo Limited Macrocyclic compounds
JPWO2020122022A1 (ja) * 2018-12-10 2021-10-28 東京都 肝機能改善剤
WO2021160617A1 (en) * 2020-02-11 2021-08-19 Irbm S.P.A. Spirocyclic inhibitors of hepatitis b virus
KR20210153908A (ko) * 2020-06-11 2021-12-20 제이더블유중외제약 주식회사 코로나바이러스감염증-19(covid-19) 치료용 조성물
CN113730403A (zh) * 2021-09-26 2021-12-03 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 化合物kya1797k制备抗hbv病毒药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06505486A (ja) 1991-02-07 1994-06-23 モレキュメティクス，リミティド βターンおよびβバルジのコンフォメーション的に制限された模倣物およびそれらを含有するペプチド
JPH07509723A (ja) 1992-08-06 1995-10-26 モレキュメティクス，リミティド 反転型ターンの立体配座的に拘束されたミメティックスと前者を含有するペプチド
US6184223B1 (en) 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6013458A (en) * 1995-10-27 2000-01-11 Molecumetics, Ltd. Reverse-turn mimetics and methods relating thereto
US6294525B1 (en) 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
AU2006227776A1 (en) * 2005-03-18 2006-09-28 Institute For Chemical Genomics Alpha-helix mimetics and methods relating to the treatment of fibrosis
US20070129353A1 (en) 2005-11-08 2007-06-07 Michael Kahn Alpha-helix mimetics and method relating to the treatment of cancer stem cells
WO2007056513A1 (en) 2005-11-08 2007-05-18 Institute For Chemical Genomics α-HELIX MIMETICS AND METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS
KR101671535B1 (ko) 2008-06-06 2016-11-01 가부시키가이샤 프리즘 파마 알파 나선 모방체 및 이와 관련된 방법
WO2010044485A1 (en) 2008-10-14 2010-04-22 Prism Biolab Corporation Alpha helix mimetics in the treatment of cancer
WO2010128685A1 (en) 2009-05-07 2010-11-11 Prism Biolab Corporation Alpha helix mimetics and methods relating thereto
US20130274215A1 (en) * 2010-04-08 2013-10-17 Fate Therapeutics, Inc. Pharmaceutical compositions to treat fibrosis
JP2014509298A (ja) * 2011-02-25 2014-04-17 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ アルファへリックスミメティック及びその関連の方法
WO2014092154A1 (ja) * 2012-12-12 2014-06-19 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ 肝線維症の予防または治療剤

Also Published As

Publication number Publication date
WO2015056104A2 (en) 2015-04-23
EP3057590B1 (en) 2019-11-27
WO2015056104A3 (en) 2015-06-18
US20160263131A1 (en) 2016-09-15
EP3057590A4 (en) 2017-06-07
JP6507336B2 (ja) 2019-05-08
JP2016535082A (ja) 2016-11-10
EP3057590A2 (en) 2016-08-24

Similar Documents

Publication Publication Date Title
JP6507336B2 (ja) Ｃｂｐ／カテニン阻害剤を用いる肝線維症の治療
Ryu et al. Dasatinib regulates LPS-induced microglial and astrocytic neuroinflammatory responses by inhibiting AKT/STAT3 signaling
Song et al. NETs promote ALI/ARDS inflammation by regulating alveolar macrophage polarization
WO2009045397A1 (en) Methods for treating polycystic kidney desease (pkd) or other cyst forming diseases
Chen et al. A novel MyD88 inhibitor LM9 prevents atherosclerosis by regulating inflammatory responses and oxidative stress in macrophages
JP2013529627A (ja) ヒドロキシクロロキンまたはヒドロキシクロロキンおよび抗ウイルス剤の組合せを使用するｃ型肝炎ウイルス関連疾患の処置
JP2010520200A (ja) 特定のマトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤を使用する肝疾患を治療する方法
Guan et al. Dysregulated chemokine signaling in cystic fibrosis lung disease: A potential therapeutic target
Li et al. Dexmedetomidine attenuates lung injury in toxic shock rats by inhibiting inflammation and autophagy
Lei et al. Synergistic neuroprotective effect of rasagiline and idebenone against retinal ischemia-reperfusion injury via the Lin28-let-7-Dicer pathway
Mo et al. NLRP3 inflammasome in cardiovascular diseases: an update
Benitez et al. Cortistatin regulates fibrosis and myofibroblast activation in experimental hepatotoxic‐and cholestatic‐induced liver injury
Kai-Lan et al. Pretreatment with erythropoietin attenuates intestinal ischemia reperfusion injury by further promoting PI3K/Akt signaling activation
Liu et al. Natural molecule isoliquiritigenin mitigates MASH and liver fibrosis in mice by promoting autophagy through the PI3K/Akt signaling pathway
Cheon et al. Niclosamide suppresses RANKL-induced osteoclastogenesis and prevents LPS-induced bone loss
JP2021527669A (ja) 線維症の軽減又は治療のための組成物及び方法
JP2015534942A (ja) Ｃｂｐ／カテニン阻害剤を用いる過剰増殖性及び前がん性皮膚病の治療
WO2019103984A1 (en) Compositions including fatp1, fatp3, fatp4, fatp5, and/or fatp6 inhibitors and uses thereof
Yin et al. Renal fibrosis: research progress on mechanisms and therapeutic strategies
US20160166577A1 (en) Treatment of pulmonary fibrosis using an inhibitor of cbp/catenin
JP2006504769A (ja) 病理学的プロセスに関する遺伝子発現を制御するためのキナゾリノン組成物
EP4144350B1 (en) Treatment or prevention of vascular malformation
KR102715760B1 (ko) 카테콜아민/adrb2 매개 간질환 치료제 스크리닝 방법
WO2018062895A1 (ko) 오스문드아세톤 또는 이의 약학적으로 허용가능한 염을 포함하는 골 질환 예방 또는 치료용 조성물
Abouelhamd et al. Investigating the Hepatoprotective Properties of Entresto in Hepatic Ischemia‐Reperfusion Injury in Rats: The Implication of TLR4/MYD88/NF‐KB p‐65 and PPAR‐γ/HO‐1/Nrf2 Pathways

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160824

WD01 Invention patent application deemed withdrawn after publication